Postponing surgery
OtherPostponing surgery for patients with Sars-cov-2 infection
NCT Number: NCT05336110
The deployment of vaccination against SARS-CoV-2 from 2021 led to a modification in June 2021of previous recommendations concerning the postponing scheduled surgery suggesting local adaptations of this delay if epidemic developments appear. Today, the evolutions of the pandemic make these recommendations obsolete and impose the updating of the data produced during the first epidemic wave of 2020. Among these evolutions, the two most important are the existence of a large vaccination coverage on the one hand and the emergence of variants of lesser severity on the other hand
Looking for future studies?
Notify Me18 year and older
All sexes
Observational
CHU d'Amiens, Amiens, France
Previous studies performed during the first COVID-19 epidemic wave in the first half of 2020 led to the recommendation, after taking into account the individual risk-benefit balance, of postponing scheduled surgery for ideally at least 6 completed weeks in a patient with a positive preoperative SARS-CoV-2 PCR.
The deployment of vaccination against SARS-CoV-2 from 2021 led to a modification of these recommendations in June 2021 suggesting local adaptations of this delay if epidemic developments appear. Today, the evolutions of the pandemic make these recommendations obsolete and impose the updating of the data produced during the first epidemic wave of 2020. Among these evolutions, the two most important are the existence of a large vaccination coverage on the one hand and the emergence of variants of lesser severity on the other hand
Healthy volunteers accepted: No
Only the study team can determine whether someone qualifies for participation.
Inclusion criteria
Exclusion criteria
Postponing surgery for patients with Sars-cov-2 infection
Time frame: up to 30 postoperative days.
The primary endpoint will be a composite endpoint, that consist of respiratory morbidity associated with occurrence of pneumonia (bacterial or viral), acute respiratory distress, symptomatic pulmonary embolism (i.e. having led to a diagnostic procedure and a treatment), and postoperative prolongation of mechanical ventilation or the use of unscheduled, during the postoperative hospital stay and within the limit of 30 postoperative days.
Time frame: up to 30 postoperative days.
The secondary endpoints will be the hospital mortality (number of death during hospitalization)
Time frame: up to 30 postoperative days.
The secondary endpoints will be the mortality at D30 (number of death since surgery until Day 30);
Time frame: up to 30 postoperative days.
The secondary endpoints will be the number of occurrence of a deep vein thrombosis (excluding pulmonary embolism),
Time frame: up to 30 postoperative days.
The secondary endpoints will be the numberof non-respiratory infection or septic shock during the post-operative hospital stay and within the limit of postoperative 30 days.
Time frame: up to 30 postoperative days.
The secondary endpoints will be the number of non-respiratory infection or septic shock during the post-operative hospital stay and within the limit of postoperative 30 days.
Time frame: up to 30 postoperative days.
The secondary endpoints will be the length of hospital stay, length of critical care stay (if hospitalization in critical care).
Time frame: up to 30 postoperative days.
The secondary endpoints will be the need for re-hospitalization during the first 30 days after surgery (number of patients with re-hospitalization)
Société Française d'Anesthésie et de Réanimation
Other
Assessment of the Impact of the Postponement of Surgery on the Postoperative Morbidity After Sars-cov-2 Infection in 2022
Acronym: DROMIS-22
OpenTrials presents study information sourced from ClinicalTrials.gov. The official registry record should be consulted for the latest information.
View the official ClinicalTrials.gov record (opens in a new tab)This listing is for discovery and informational purposes only. It is not medical advice, does not guarantee that a study is recruiting, and does not determine eligibility. Contact the study team and a qualified healthcare professional when considering participation.
Published trials that share one or more normalized conditions with this study.
NCT06633835
COVID-19, Coronaviridae Infections
Salt Lake City, Utah, United States
View Trial DetailsNCT06234956
COVID-19, Coronaviridae Infections
Barcelona, Spain
View Trial DetailsNCT07408297
COVID -19, COVID-19
Kisumu, Kenya
View Trial DetailsNCT06065176
COVID-19, Coronaviridae Infections
Salt Lake City, Utah, United States
View Trial Details